Abstract
This important new strategic report from Espicom evaluates the CNS generic
drug market and provides detailed assessment and forecast for leading products
by value to 2012, patent expiry opportunities to 2015 and competitive
evaluation.
Sales of the leading branded drugs used to treat the major CNS conditions
could exceed US$70 billion in 2008, with a number of these losing patent
protection in the coming years.
This important new strategic report evaluates the CNS generic drug market
sector and answers key questions such as:
- What is the patent and data exclusivity status of Shire' s ADHD drug
Adderall?
- What impact on sales of GSK' s Seroxat/Paxil will generic competition have
from 2007?
- What opportunities exist for Wyeth' s valuable SSNRI Effexor?
- What strategies are sanofi-aventis employing in defence of its best
selling insomnia treatment Ambien?
- Only Exelon is currently available generically for the treatment of
Alzheimer' s - what is the potential of the other leading treatments Aricept
(Eisai), Razadyne (Janssen) and Namenda (Forest Labs)?
- What' s in the pipeline? New branded products that will compete with
generics in the future.
- Why will sales of Eli Lilly' s Zyprexa remain constant over the next 5
years despite rising generic availability?
- What are Dr Reddy' s CNS drug interests?
- In 2007, Caraco Pharmaceuticals received 3 ANDA approvals for CNS drugs.
What were they and in what dosages?
Providing…
- Detailed assessment and forecast for leading products by value to 2012 and
beyond
- An assessment of patent expiry and challenges
- Competitive evaluation
- A review of products in late phase research which could impact generic
developments
- Patent expiry opportunities to 2015
All major sectors
- Neurodegenerative Diseases
- (Alzheimer' s and Parkinson' s Diseases)
- Depression
- Multiple Sclerosis
- ADHD
- Insomnia
| 
View Cart
